Huang, J. et al. Worldwide burden of, risk factors for, and trends in pancreatic cancer. Gastroenterology 160, 744–754 (2021).
Abboud, Y. et al. Increasing pancreatic cancer incidence in young women in the United States: a population-based time-trend analysis, 2001–2018. Gastroenterology 164, 978–989.e6 (2023).
Koh, B. et al. Patterns in cancer incidence among people younger than 50 years in the US, 2010 to 2019. JAMA Netw. Open. 6, e2328171 (2023).
Allemani, C. et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391, 1023–1075 (2018).
Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12–49 (2024).
NHS England. Cancer survival in England, cancers diagnosed 2015 to 2019, followed up to 2020. NHS Digital digital.nhs.uk/data-and-information/publications/statistical/cancer-survival-in-england/cancers-diagnosed-2015-to-2019-followed-up-to-2020 (2022).
Rahib, L. et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74, 2913–2921 (2014).
Casolino, R. et al. Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Ann. Oncol. 32, 183–196 (2020).
Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817–1825 (2011).
Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691–1703 (2013).
Riedl, J. M. et al. Gemcitabine/nab-paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: a propensity score analysis. Eur. J. Cancer 151, 3–13 (2021).
Cho, I. R. et al. FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: single-center cohort study. World J. Gastrointest. Oncol. 12, 182–194 (2020).
Wang-Gillam, A. et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387, 545–557 (2016).
Nichetti, F. et al. NALIRIFOX vs FOLFIRINOX vs gemcitabine plus nab-paclitaxel as first-line treatment of advanced pancreatic cancer: an individual patient data pooled analysis of phase 3 registration trials [abstract]. J. Clin. Oncol. 41, e16262 (2023).
Springfeld, C. et al. Neoadjuvant therapy for pancreatic cancer. Nat. Rev. Clin. Oncol. 20, 318–337 (2023).
Cameron, J. L. & He, J. Two thousand consecutive pancreaticoduodenectomies. J. Am. Coll. Surg. 220, 530–536 (2015).
Neoptolemos, J. P. et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304, 1073–1081 (2010).
Neoptolemos, J. P. et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389, 1011–1024 (2017).
Neoptolemos, J. P. et al. ESPAC-4: a multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma: five year follow-up [abstract]. J. Clin. Oncol. 38, 4516 (2020).
Ghaneh, P. et al. ESPAC-5F: four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer [abstract]. J. Clin. Oncol. 38, 4505 (2020).
Conroy, T. et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N. Engl. J. Med. 379, 2395–2406 (2018).
Sugawara, T. et al. Association of adjuvant chemotherapy in patients with resected pancreatic adenocarcinoma after multiagent neoadjuvant chemotherapy. JAMA Oncol. 9, 316–323 (2022).
Conroy, T. et al. Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial. JAMA Oncol. 8, 1571–1578 (2022).
Tempero, M. A. et al. Adjuvant nab-paclitaxel + gemcitabine in resected pancreatic ductal adenocarcinoma: results from a randomized, open-label, phase III trial. J. Clin. Oncol. 41, 2007–2019 (2022).
Tempero, M. A. et al. NCCN guidelines: pancreatic adenocarcinoma. NCCN www.nccn.org/guidelines/guidelines-detail?category=1&id=1455 (2025).
Strobel, O., Neoptolemos, J., Jäger, D. & Büchler, M. W. Optimizing the outcomes of pancreatic cancer surgery. Nat. Rev. Clin. Oncol. 16, 11–26 (2019).
Tung, S. et al. Population-level symptom assessment following pancreaticoduodenectomy for adenocarcinoma. JAMA Surg. 154, e193348 (2019).
Halloran, C. M. et al. A multicenter, randomized, double-blinded, clinical trial comparing Cattell–Warren and Blumgart anastomoses following partial pancreatoduodenectomy: PANasta trial. Ann. Surg. Open. 3, e198 (2022).
Dreyer, S. B. et al. Precision oncology in surgery: patient selection for operable pancreatic cancer. Ann. Surg. 272, 366–376 (2020).
Mackay, T. M. et al. The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis. HPB 22, 233–240 (2020).
Ghaneh, P. et al. The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Ann. Surg. 269, 520–529 (2019).
Jamieson, N. B. et al. Positive mobilization margins alone do not influence survival following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma. Ann. Surg. 251, 1003–1010 (2010).
Dreyer, S. B. et al. The impact of molecular subtyping on pathological staging of pancreatic cancer. Ann. Surg. 277, e396–e405 (2021).
Murphy, J. E. et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol. 4, 963–969 (2018).
Versteijne, E. et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J. Clin. Oncol. 40, 1220–1230 (2022).
Murphy, J. E. et al. Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2019.0892 (2019).
Groot Koerkamp, B. et al. Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): a multicenter randomized controlled trial [abstract LBA83]. Ann. Oncol. 34, S1323 (2023).
Labori, K. J. et al. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol. Hepatol. 9, 205–217 (2024).
Chawla, A. et al. Alliance A021806: a phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer [abstract]. J. Clin. Oncol. 41, TPS4204 (2023).
van Dam, J. L. et al. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial. BMC Cancer 23, 728 (2023).
Neoptolemos, J. P. et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 350, 1200–1210 (2004).
Hammel, P. et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA 315, 1844–1853 (2016).
Fietkau, R. et al. Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: first results of the CONKO-007 trial [abstract]. J. Clin. Oncol. 40, 4008 (2022).
Doleh, Y., Lal, L. S., Blauer-Petersen, C., Antico, G. & Pishvaian, M. Treatment patterns and outcomes in pancreatic cancer: retrospective claims analysis. Cancer Med. 9, 3463–3476 (2020).
Kordes, M., Larsson, L., Engstrand, L. & Löhr, J.-M. Pancreatic cancer cachexia: three dimensions of a complex syndrome. Br. J. Cancer 124, 1623–1636 (2021).
Mitsunaga, S., Kasamatsu, E. & Machii, K. Incidence and frequency of cancer cachexia during chemotherapy for advanced pancreatic ductal adenocarcinoma. Support. Care Cancer 28, 5271–5279 (2020).
Kays, J. K. et al. Three cachexia phenotypes and the impact of fat-only loss on survival in FOLFIRINOX therapy for pancreatic cancer. J. Cachexia Sarcopenia Muscle 9, 673–684 (2018).
Gerstberger, S., Jiang, Q. & Ganesh, K. Metastasis. Cell 186, 1564–1579 (2023).
Patel, S. A., Rodrigues, P., Wesolowski, L. & Vanharanta, S. Genomic control of metastasis. Br. J. Cancer 124, 3–12 (2021).
Bielski, C. M. et al. Genome doubling shapes the evolution and prognosis of advanced cancers. Nat. Genet. 50, 1189–1195 (2018).
Lee, J. W. et al. Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature 567, 249–252 (2019).
Karamitopoulou, E. et al. Spatially restricted tumour-associated and host-associated immune drivers correlate with the recurrence sites of pancreatic cancer. Gut 72, 1523–1533 (2023).
Dreyer, S. B. et al. Genomic and molecular analyses identify molecular subtypes of pancreatic cancer recurrence. Gastroenterology 162, 320–324.e4 (2021).
Rhim, A. D. et al. EMT and dissemination precede pancreatic tumor formation. Cell 148, 349–361 (2012).
Grünwald, B. et al. Pancreatic premalignant lesions secrete tissue inhibitor of metalloproteinases-1, which activates hepatic stellate cells via CD63 signaling to create a premetastatic niche in the liver. Gastroenterology 151, 1011–1024.e7 (2016).
Costa-Silva, B. et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat. Cell Biol. 17, 816–826 (2015).
Hoshino, A. et al. Tumour exosome integrins determine organotropic metastasis. Nature 527, 329–335 (2015).
Xu, Z. et al. Role of pancreatic stellate cells in pancreatic cancer metastasis. Am. J. Pathol. 177, 2585–2596 (2010).
Zhang, S. et al. Single cell transcriptomic analyses implicate an immunosuppressive tumor microenvironment in pancreatic cancer liver metastasis. Nat. Commun. 14, 5123 (2023).
Bretthauer, M. & Kalager, M. Principles, effectiveness and caveats in screening for cancer. Br. J. Surg. 100, 55–65 (2013).
Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114–1117 (2010).
Overbeek, K. A. et al. Timeline of development of pancreatic cancer and implications for successful early detection in high-risk individuals. Gastroenterology 162, 772–785.e4 (2022).
Yu, J., Blackford, A. L., Dal Molin, M., Wolfgang, C. L. & Goggins, M. Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. Gut 64, 1783–1789 (2015).
Notta, F. et al. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature 538, 378–382 (2016).
Crippa, S. et al. Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics. Clin. Gastroenterol. Hepatol. 8, 213–219 (2010).
Goh, B. K. P. et al. A review of mucinous cystic neoplasms of the pancreas defined by ovarian-type stroma: clinicopathological features of 344 patients. World J. Surg. 30, 2236–2245 (2006).
Nilsson, L. N. et al. Nature and management of pancreatic mucinous cystic neoplasm (MCN): a systematic review of the literature. Pancreatology 16, 1028–1036 (2016).
Park, J. W. et al. Mucinous cystic neoplasm of the pancreas: is surgical resection recommended for all surgically fit patients? Pancreatology 14, 131–136 (2014).
Springer, S. et al. A combination of molecular markers and clinical features improve the classification of pancreatic cysts. Gastroenterology 149, 1501–1510 (2015).
Lennon, A. M. & Canto, M. I. Pancreatic cysts – part 2: should we be less cyst centric? Pancreas 46, 745–750 (2017).
Marchegiani, G. et al. Surveillance for presumed BD-IPMN of the pancreas: stability, size, and age identify targets for discontinuation. Gastroenterology 165, 1016–1024.e5 (2023).
Pezzilli, R. et al. Epidemiology, clinical features and diagnostic work-up of cystic neoplasms of the pancreas: interim analysis of the prospective PANCY survey. Dig. Liver Dis. 52, 547–554 (2020).
Marchegiani, G. et al. IPMN involving the main pancreatic duct: biology, epidemiology, and long-term outcomes following resection. Ann. Surg. 261, 976–983 (2015).
Hata, T. et al. Genome-wide somatic copy number alterations and mutations in high-grade pancreatic intraepithelial neoplasia. Am. J. Pathol. 188, 1723–1733 (2018).
Braxton, A. M. et al. 3D genomic mapping reveals multifocality of human pancreatic precancers. Nature 629, 679–687 (2024).
Søreide, K. & Marchegiani, G. Clinical management of pancreatic premalignant lesions. Gastroenterology 162, 379–384 (2022).
Søreide, K., Ismail, W., Roalsø, M., Ghotbi, J. & Zaharia, C. Early diagnosis of pancreatic cancer: clinical premonitions, timely precursor detection and increased curative-intent surgery. Cancer Control. 30, 10732748231154711 (2023).
Cao, K. et al. Large-scale pancreatic cancer detection via non-contrast CT and deep learning. Nat. Med 29, 3033–3043 (2023).
Goggins, M. et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 69, 7–17 (2019).
Henrikson, N. B. et al. Screening for pancreatic cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 322, 445–454 (2019).
Vasen, H. et al. Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three European expert centers. J. Clin. Oncol. 34, 2010–2019 (2016).
Oldfield, L. et al. United Kingdom Early Detection Initiative (UK-EDI): protocol for establishing a national multicentre cohort of individuals with new-onset diabetes for early detection of pancreatic cancer. BMJ Open. 12, e068010 (2022).
US Preventive Services Task Force. Screening for pancreatic cancer: US Preventive Services Task Force reaffirmation recommendation statement. JAMA 322, 438–444 (2019).
Ferrer, M. et al. Cachexia: a systemic consequence of progressive, unresolved disease. Cell 186, 1824–1845 (2023).
Roberts, K. J., Bannister, C. A. & Schrem, H. Enzyme replacement improves survival among patients with pancreatic cancer: results of a population based study. Pancreatology 19, 114–121 (2019).
Roberts, K. J. et al. Pancreas exocrine replacement therapy is associated with increased survival following pancreatoduodenectomy for periampullary malignancy. HPB 19, 859–867 (2017).
Abraham, J. P. et al. Clinical validation of a machine-learning-derived signature predictive of outcomes from first-line oxaliplatin-based chemotherapy in advanced colorectal cancer. Clin. Cancer Res. 27, 1174–1183 (2021).
Graham, J. S. et al. PRIMUS-001: an adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation (ISRCTN75002153) – part of Precision-Panc [abstract]. J. Clin. Oncol. 36, TPS4158 (2018).
Dreyer, S. B. et al. PRECISION-panc: the next generation therapeutic development platform for pancreatic cancer. Clin. Oncol. 32, 1–4 (2020).
Dreyer, S. B. et al. Pancreatic cancer: from genome discovery to PRECISION-panc. Clin. Oncol. 32, 5–8 (2020).
Knox, J. J. et al. PASS-01: pancreatic adenocarcinoma signature stratification for treatment–01 [abstract]. J. Clin. Oncol. 40, TPS635 (2022).
Dreyer, S. B. et al. Targeting DNA damage response and replication stress in pancreatic cancer. Gastroenterology 160, 362–377.e13 (2021).
Dreyer, S. B., Chang, D. K., Bailey, P. & Biankin, A. V. Pancreatic cancer genomes: implications for clinical management and therapeutic development. Clin. Cancer Res. 23, 1638–1646 (2017).
Waddell, N. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495–501 (2015).
Casolino, R. et al. Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis. J. Clin. Oncol. 39, 2617–2631 (2021).
ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature 578, 82–93 (2020).
Golan, T. et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N. Engl. J. Med. 381, 317–327 (2019).
Kindler, H. L. et al. Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J. Clin. Oncol. 40, 3929–3939 (2022).
Batalini, F. et al. Homologous recombination deficiency landscape of breast cancers and real-world effectiveness of poly ADP-ribose polymerase inhibitors in patients with somatic BRCA1/2, germline PALB2, or homologous recombination deficiency signature. JCO Precis. Oncol. 7, e2300091 (2023).
Moore, K. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379, 2495–2505 (2018).
Davies, H. et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat. Med. 23, 517–525 (2017).
Chopra, N. et al. Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer. Nat. Commun. 11, 2662 (2020).
González-Martín, A. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 381, 2391–2402 (2019).
Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47–52 (2016).
Biankin, A. V. et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491, 399–405 (2012).
Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32, 185–203.e13 (2017).
Clark, C. E. et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 67, 9518–9527 (2007).
Cullis, J., Das, S. & Bar-Sagi, D. Kras and tumor immunity: friend or foe? Cold Spring Harb. Perspect. Med. 8, a031849 (2018).
Chan-Seng-Yue, M. et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat. Genet. 52, 463 (2020).
Connor, A. A. et al. Integration of genomic and transcriptional features in pancreatic cancer reveals increased cell cycle progression in metastases. Cancer Cell 35, 267–282.e7 (2019).
Link, J. M. et al. Ongoing replication stress tolerance and clonal T cell responses distinguish liver and lung recurrence and outcomes in pancreatic cancer. Nat. Cancer 6, 123–144 (2025).
Moffitt, R. A. et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat. Genet. 47, 1168–1178 (2015).
Collisson, E. A., Bailey, P., Chang, D. K. & Biankin, A. V. Molecular subtypes of pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 16, 207–220 (2019).
Collisson, E. A. et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 17, 500–503 (2011).
Brunton, H. et al. HNF4A and GATA6 loss reveals therapeutically actionable subtypes in pancreatic cancer. Cell Rep. 31, 107625 (2020).
George, B. et al. Transcriptomic-based microenvironment classification reveals precision medicine strategies for pancreatic ductal adenocarcinoma. Gastroenterology 166, 859–871.e3 (2024).
Wang, Y. et al. Single-cell analysis of pancreatic ductal adenocarcinoma identifies a novel fibroblast subtype associated with poor prognosis but better immunotherapy response. Cell Discov. 7, 36 (2021).
Rashid, N. U. et al. Purity independent subtyping of tumors (PurIST), a clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer. Clin. Cancer Res. 26, 82–92 (2019).
O’Kane, G. M. et al. GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer. Clin. Cancer Res. 26, 4901–4910 (2020).
Grünwald, B. T. et al. Spatially confined sub-tumor microenvironments in pancreatic cancer. Cell 184, 5577–5592 (2021).
Hingorani, S. R. Epithelial and stromal co-evolution and complicity in pancreatic cancer. Nat. Rev. Cancer 23, 57–77 (2023).
Topham, J. T. et al. Subtype-discordant pancreatic ductal adenocarcinoma tumors show intermediate clinical and molecular characteristics. Clin. Cancer Res. 27, 150–157 (2021).
Candido, J. B. et al. CSF1R+ macrophages sustain pancreatic tumor growth through T cell suppression and maintenance of key gene programs that define the squamous subtype. Cell Rep. 23, 1448–1460 (2018).
Chou, A. et al. Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Med. 5, 78 (2013).
Strickler, J. H. et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer. N. Engl. J. Med. 388, 33–43 (2023).
Sacher, A. et al. Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation. N. Engl. J. Med. 389, 710–721 (2023).
Bekaii-Saab, T. S. et al. Adagrasib in advanced solid tumors harboring a KRASG12C mutation. J. Clin. Oncol. 41, 4097–4106 (2023).
Lito, P., Solomon, M., Li, L.-S., Hansen, R. & Rosen, N. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science 351, 604–608 (2016).
Kemp, S. B. et al. Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer. Cancer Discov. 13, 298–311 (2023).
Park, W. et al. Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC) [abstract 608O]. Ann. Oncol. 35, S486–S487 (2024).
Hallin, J. et al. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat. Med. 28, 2171–2182 (2022).
Singhal, A., Li, B. T. & O’Reilly, E. M. Targeting KRAS in cancer. Nat. Med. 30, 969–983 (2024).
Wasko, U. N. et al. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Nature 629, 927–936 (2024).
Arbour, K. C. et al. Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) [abstract 652O]. Ann. Oncol. 34, S458 (2023).
Jiang, J. et al. Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers. Cancer Discov. 14, 994–1017 (2024).
Gulay, K. C. M. et al. Dual Inhibition of KRASG12D and pan-ERBB is synergistic in pancreatic ductal adenocarcinoma. Cancer Res. 83, 3001–3012 (2023).
Huynh, M. V. et al. Functional and biological heterogeneity of KRASQ61 mutations. Sci. Signal. 15, eabn2694 (2022).
Hobbs, G. A. et al. Atypical KRASG12R mutant is impaired in PI3K signaling and macropinocytosis in pancreatic cancer. Cancer Discov. 10, 104–123 (2020).
Masuishi, T. et al. Sotorasib (Soto) + panitumumab (Pmab) and FOLFIRI in previously treated KRASG12C-mutated metastatic colorectal cancer (mCRC): safety and efficacy for CodeBreaK 101 phase Ib expansion cohort [abstract 92MO]. Ann. Oncol. 34, S1505 (2023).
Mugarza, E. et al. Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers. Sci. Adv. 8, eabm8780 (2022).
Simnica, D. & Kobold, S. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N. Engl. J. Med. 387, 573 (2022).
Sim, M. J. W. et al. High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D. Proc. Natl Acad. Sci. USA 117, 12826–12835 (2020).
Poole, A. et al. Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen. Nat. Commun. 13, 5333 (2022).
Lu, D. et al. KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors. Nat. Commun. 14, 6389 (2023).
Huff, A. L. et al. A pooled mutant KRAS peptide vaccine activates polyfunctional T cell responses in patients with resected pancreatic cancer [abstract]. Cancer Res. 83, LB197 (2023).
Haldar, S. D. et al. Mutant KRAS peptide-based vaccine in patients at high risk of developing pancreatic cancer: preliminary analysis from a phase I study [abstract]. Cancer Res. 84, CT022 (2024).
Provenzano, P. P. et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21, 418–429 (2012).
DuFort, C. C. et al. Interstitial pressure in pancreatic ductal adenocarcinoma is dominated by a gel-fluid phase. Biophys. J. 110, 2106–2119 (2016).
Hingorani, S. R. et al. Phase Ib study of PEGylated recombinant human hyaluronidase and gemcitabine in patients with advanced pancreatic cancer. Clin. Cancer Res. 22, 2848–2854 (2016).
Hingorani, S. R. et al. HALO 202: randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. J. Clin. Oncol. 36, 359–366 (2018).
Van Cutsem, E. et al. Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma. J. Clin. Oncol. 38, 3185–3194 (2020).
Lander, V. E. et al. Stromal reprogramming by FAK inhibition overcomes radiation resistance to allow for immune priming and response to checkpoint blockade. Cancer Discov. 12, 2774–2799 (2022).
Biffi, G. et al. IL1-Induced JAK/STAT signaling is antagonized by TGFβ to shape CAF heterogeneity in pancreatic ductal adenocarcinoma. Cancer Discov. 9, 282–301 (2019).
Öhlund, D. et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J. Exp. Med. 214, 579–596 (2017).
Bryce, A. S., Dreyer, S. B., Froeling, F. E. M. & Chang, D. K. Exploring the biology of cancer-associated fibroblasts in pancreatic cancer. Cancers 14, 5302 (2022).
Lee, B. Y. et al. Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasis. Nat. Commun. 12, 7336 (2021).
Hutton, C. et al. Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity. Cancer Cell 39, 1227–1244.e20 (2021).
Biffi, G. & Tuveson, D. A. Diversity and biology of cancer-associated fibroblasts. Physiol. Rev. 101, 147–176 (2021).
Elyada, E. et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discov. 9, 1102–1123 (2019).
Chen, K. et al. Single-cell RNA-seq reveals dynamic change in tumor microenvironment during pancreatic ductal adenocarcinoma malignant progression. eBioMedicine 66, 103315 (2021).
Froeling, F. E. M. et al. Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression. Gastroenterology 141, 1486–1497.e14 (2011).
Hingorani, S. R. et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469–483 (2005).
Sherman, M. H. et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159, 80–93 (2014).
Gorchs, L. et al. The vitamin D analogue calcipotriol promotes an anti-tumorigenic phenotype of human pancreatic CAFs but reduces T cell mediated immunity. Sci. Rep. 10, 17444 (2020).
Balachandran, V. P., Beatty, G. L. & Dougan, S. K. Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities. Gastroenterology 156, 2056–2072 (2019).
Garcia Garcia, C. J. et al. Stromal HIF2 regulates immune suppression in the pancreatic cancer microenvironment. Gastroenterology 162, 2018–2031 (2022).
Huang, H. et al. Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Cancer Cell 40, 656–673.e7 (2022).
Ho, W. J., Jaffee, E. M. & Zheng, L. The tumour microenvironment in pancreatic cancer – clinical challenges and opportunities. Nat. Rev. Clin. Oncol. 17, 527–540 (2020).
Danilova, L. et al. Programmed cell death ligand-1 (PD-L1) and CD8 expression profiling identify an immunologic subtype of pancreatic ductal adenocarcinomas with favorable survival. Cancer Immunol. Res. 7, 886–895 (2019).
Hiraoka, N., Onozato, K., Kosuge, T. & Hirohashi, S. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin. Cancer Res. 12, 5423–5434 (2006).
Kobayashi, N. et al. FOXP3+ regulatory T cells and tumoral indoleamine 2,3-dioxygenase expression predicts the carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas. Pancreatology 10, 631–640 (2010).
Mota Reyes, C. et al. Regulatory T cells in pancreatic cancer: of mice and men. Cancers 14, 4582 (2022).
Dawod, B. et al. Myeloid-derived suppressor cell depletion therapy targets IL-17A-expressing mammary carcinomas. Sci. Rep. 10, 13343 (2020).
Joshi, N. S. et al. Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses. Immunity 43, 579–590 (2015).
Jang, J.-E. et al. Crosstalk between regulatory T cells and tumor-associated dendritic cells negates anti-tumor immunity in pancreatic cancer. Cell Rep. 20, 558–571 (2017).
Lee, J. W., Komar, C. A., Bengsch, F., Graham, K. & Beatty, G. L. Genetically engineered mouse models of pancreatic cancer: the KPC model (LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-cre), its variants, and their application in immuno-oncology drug discovery. Curr. Protoc. Pharmacol. 73, 14.39.1–14.39.20 (2016).
Stromnes, I. M. et al. Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut 63, 1769–1781 (2014).
Steele, C. W. et al. CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell 29, 832–845 (2016).
US National Library of Medicine. ClinicalTrials.gov clinicaltrials.gov/study/NCT02583477?tab=results (2019).
Väyrynen, S. A. et al. Composition, spatial characteristics, and prognostic significance of myeloid cell infiltration in pancreatic cancer. Clin. Cancer Res. 27, 1069–1081 (2021).
Kersten, K. et al. Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer. Cancer Cell 40, 624–638.e9 (2022).
Caronni, N. et al. IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancer. Nature 623, 415–422 (2023).
Zhu, Y. et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 74, 5057–5069 (2014).
Alonso-Nocelo, M. et al. Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma. Gut 72, 345–359 (2022).
Bellomo, G. et al. Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6/AXL signalling axis. Gut 71, 2284–2299 (2022).
Sun, X. et al. Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism. Gut 71, 129–147 (2021).
van Eijck, C. W. F. et al. Enhanced antitumour immunity following neoadjuvant chemoradiotherapy mediates a favourable prognosis in women with resected pancreatic cancer. Gut 73, 311–324 (2023).
Halbrook, C. J. et al. Macrophage-released pyrimidines inhibit gemcitabine therapy in pancreatic cancer. Cell Metab. 29, 1390–1399.e6 (2019).
Dixit, A. et al. Targeting TNF-α-producing macrophages activates antitumor immunity in pancreatic cancer via IL-33 signaling. JCI Insight 7, e153242 (2022).
Datta, J. et al. Combined MEK and STAT3 inhibition uncovers stromal plasticity by enriching for cancer-associated fibroblasts with mesenchymal stem cell-like features to overcome immunotherapy resistance in pancreatic cancer. Gastroenterology 163, 1593–1612 (2022).
Beatty, G. L. et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612–1616 (2011).
Hallett, R. M. et al. Therapeutic targeting of LIF overcomes macrophage-mediated immunosuppression of the local tumor microenvironment. Clin. Cancer Res. 29, 791–804 (2023).
Ho, W. J. et al. Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways. Genome Biol. 22, 154 (2021).
Yang, J. et al. Integrated genomic and transcriptomic analysis reveals unique characteristics of hepatic metastases and pro-metastatic role of complement C1q in pancreatic ductal adenocarcinoma. Genome Biol. 22, 4 (2021).
Zhang, Y. et al. PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules. J. Pathol. Clin. Res. 8, 257–267 (2022).
Ott, P. A. et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J. Clin. Oncol. 37, 318–327 (2019).
Coston, T. et al. Efficacy of immune checkpoint inhibition and cytotoxic chemotherapy in mismatch repair-deficient and microsatellite instability-high pancreatic cancer: Mayo Clinic experience. JCO Precis. Oncol. 7, e2200706 (2023).
Taïeb, J. et al. Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort. Eur. J. Cancer 188, 90–97 (2023).
O’Connor, C. A. et al. Lynch syndrome and somatic mismatch repair variants in pancreas cancer. JAMA Oncol. 10, 1511–1518 (2024).
Humphris, J. L. et al. Hypermutation in pancreatic cancer. Gastroenterology 152, 68–74.e2 (2017).
Balachandran, V. P. et al. Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature 551, 512–516 (2017).
Łuksza, M. et al. Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. Nature 606, 389–395 (2022).
Quintanilha, J. C. F. et al. Tumor mutational burden in real-world patients with pancreatic cancer: genomic alterations and predictive value for immune checkpoint inhibitor effectiveness. JCO Precis. Oncol. 7, e2300092 (2023).
Marabelle, A. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J. Clin. Oncol. 38, 1–10 (2020).
Maio, M. et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann. Oncol. 33, 929–938 (2022).
Grant, R. C. et al. Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma. Gut 70, 1894–1903 (2021).
Terrero, G. et al. Ipilimumab/nivolumab therapy in patients with metastatic pancreatic or biliary cancer with homologous recombination deficiency pathogenic germline variants. JAMA Oncol. 8, 1–3 (2022).
Chung, V. et al. Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001 [abstract]. J. Clin. Oncol. 41, TPS4198 (2023).
Macarulla, T. et al. Olaparib and durvalumab (MEDI4736) phase II study in patients with metastatic pancreatic cancer and DNA damage repair genes alterations [abstract 1686TiP]. Ann. Oncol. 34, S923 (2023).
Wainberg, Z. A. et al. Open-label, phase I study of nivolumab combined with nab-paclitaxel plus gemcitabine in advanced pancreatic cancer. Clin. Cancer Res. 26, 4814–4822 (2020).
Wang-Gillam, A. et al. A randomized phase II study of cabiralizumab (cabira) + nivolumab (nivo) ± chemotherapy (chemo) in advanced pancreatic ductal adenocarcinoma (PDAC) [abstract]. J. Clin. Oncol. 37, TPS465 (2019).
O’Hara, M. H. et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 22, 118–131 (2021).
Padrón, L. J. et al. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat. Med. 28, 1167–1177 (2022).
Borazanci, E. et al. Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors. ESMO Open. 7, 100530 (2022).
Davelaar, J. et al. Trial in progress: a randomized phase II study of pembrolizumab with or without defactinib, a focal adhesion kinase inhibitor, following chemotherapy as a neoadjuvant and adjuvant treatment for resectable pancreatic ductal adenocarcinoma (PDAC) [abstract]. J. Clin. Oncol. 40, TPS4192 (2022).
Kocher, H. M. et al. Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Nat. Commun. 11, 4841 (2020).
Perez, K. et al. Vitamin D receptor agonist paricalcitol plus gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer [abstract]. J. Clin. Oncol. 38, TPS784 (2020).
Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144–150 (2023).
Sethna, Z. et al. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Nature 639, 1042–1051 (2025).
Brown, T. J., Reiss, K. A. & O’Hara, M. H. Advancements in systemic therapy for pancreatic cancer. Am. Soc. Clin. Oncol. Educ. Book. 43, e397082 (2023).
Bazan-Peregrino, M. et al. VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. J. Immunother. Cancer 9, e003254 (2021).
da Costa, A. A. B. A., Chowdhury, D., Shapiro, G. I., D’Andrea, A. D. & Konstantinopoulos, P. A. Targeting replication stress in cancer therapy. Nat. Rev. Drug. Discov. 22, 38–58 (2022).
Philip, P. A. et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J. Clin. Oncol. 28, 3605–3610 (2010).
Qin, S. et al. Nimotuzumab plus gemcitabine for K-Ras wild-type locally advanced or metastatic pancreatic cancer. J. Clin. Oncol. 41, 5163–5173 (2023).
Singhi, A. D. et al. Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers. Gastroenterology 156, 2242–2253.e4 (2019).
Luchini, C. et al. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. J. Exp. Clin. Cancer Res. 39, 227 (2020).
Subbiah, V. et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 23, 1261–1273 (2022).
Doebele, R. C. et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 21, 271–282 (2020).
O’Reilly, E. M. & Hechtman, J. F. Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion. Ann. Oncol. 30, viii36–viii40 (2019).
Heining, C. et al. NRG1 fusions in KRAS wild-type pancreatic cancer. Cancer Discov. 8, 1087–1095 (2018).
Patil, T. et al. CRESTONE: a phase 2 study of seribantumab in adult patients with neuregulin-1 (NRG1) fusion positive locally advanced or metastatic solid tumors [abstract CT229]. Cancer Res. 83, CT229 (2023).
Schram, A. M. et al. Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements. Cancer Discov. 12, 1233–1247 (2022).
Katayama, E. S. et al. A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike? Oncotarget 11, 3489–3501 (2020).
Pryce, B. R., Wang, D. J., Zimmers, T. A., Ostrowski, M. C. & Guttridge, D. C. Cancer cachexia: involvement of an expanding macroenvironment. Cancer Cell 41, 581–584 (2023).
Ouimet, C., Fodor, B., Del Paggio, J. C. & Kimmelman, J. Proportion of patients in phase 2 oncology trials receiving treatments that are ultimately approved. J. Natl Cancer Inst. https://doi.org/10.1093/jnci/djaf013 (2025).
Marron, T. U. et al. Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery. Nat. Med. 28, 626–629 (2022).
Mills, E. J. et al. Design, analysis, and presentation of crossover trials. Trials 10, 27 (2009).
Wainberg, Z. A. et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet 402, 1272–1281 (2023).
Versteijne, E. et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J. Clin. Oncol. 38, 1763–1773 (2020).
Beer, P. A., Cooke, S. L., Chang, D. K. & Biankin, A. V. Defining the clinical genomic landscape for real-world precision oncology. Genomics 112, 5324–5330 (2020).
Leave a Reply